Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 18Hodgkin Disease 10Recurrence 8Lymphoma, Large B-Cell, Diffuse 8Lymphoma 8Leukemia, Myeloid, Acute 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Non-Hodgkin 7Breast Neoplasms 7Myelodysplastic Syndromes 6Lymphoma, Mantle-Cell 5Leukemia, Lymphocytic, Chronic, B-Cell 5Carcinoma, Non-Small-Cell Lung 5Waldenstrom Macroglobulinemia 4Neoplasms 4Melanoma 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, Extranodal NK-T-Cell 4Leukemia 4Immunoblastic Lymphadenopathy 4Glioma 4Sezary Syndrome 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Mycosis Fungoides 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Diffuse Intrinsic Pontine Glioma 3Burkitt Lymphoma 3Solid Tumors 2

Interventions

Doxorubicin 8Cyclophosphamide 8Vincristine 7Prednisone 7Etoposide 6Brentuximab Vedotin 4prednylidene 3etoposide phosphate 3Bortezomib 3pembrolizumab 2deltacortene 2Vorinostat 2Prednisolone 2Ifosfamide 2tazemetostat 1romidepsin 1pirarubicin 1duvelisib 1Salvia hispanica seed extract 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Nivolumab 1Methylprednisolone 1Methotrexate 1Melphalan 1Lenalidomide 1Lactones 1Gemcitabine 1Everolimus 1Diet, Gluten-Free 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Enteropathy-Associated T-Cell Lymphoma × Panobinostat × Clear all
NCT00901147 2014-06-27

Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma

Singapore General Hospital

Phase 2 Completed
25 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡